Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach

Verónica González-Calle, Niamh Keane, Esteban Braggio, Rafael Fonseca

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling patients with MM are currently ongoing and will provide predictive biomarkers that might support clinical decision making. In this review, we evaluate the evidence supporting the implementation of precision medicine in MM and we discuss the challenges that should be dealt with in this imminent and promising new era.

Original languageEnglish (US)
Pages (from-to)621-630
Number of pages10
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number10
StatePublished - Oct 2017


  • Actionable mutation
  • Driver
  • Immunotherapy
  • Multiple myeloma
  • Target therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach'. Together they form a unique fingerprint.

Cite this